LONDON and DUBLIN, Ireland, January 5 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (“Alltracel”), (AIM: AP.L), the medical technology company focussed on the wound care, oral care and cardiovascular health markets, announces fourth quarter revenues of EUR5.7M and full year revenue of EUR19.2M in line with the lower end of analysts’ expectations Full year preliminary results are scheduled for release in April 2006.
Highlights of the quarter include:
- m.doc(TM) brand partnerships progress with significant partnerships agreed with brand leaders in Korea and Greece, and in Russia (subject to regulatory approvals) as well as entry into the UK Professional Woundcare market in partnership with OMSCAN.
- New product development of m.doc(TM) in oral care - late stage prototypes of a number of m.doc(TM) based specialist dental blood control products have been finalised following successful concept focus groups with US dentists. A usage and attitude trial amongst US dental clinicians in partnership with a leading global dental products manufacturer is planned for this quarter.
- Significant progress on Cardio Vascular Health technology development programme -
- Pre-clinical trials on the dose-dependent efficacy of the m.doc(TM) technology platform confirmed cholesterol lowering effects in line with commercially available sterol products and in addition the findings on glucose reduction indicate diabetes management potential.
- A series of co-funded trials on m.doc(TM) in combination with sterols and with omega-3, in partnership with a number of multinational functional food manufacturers and supported by Enterprise Ireland to determine the new combined cardiovascular health benefits is agreed and beginning mid January.
- November saw the formal publication in the Life Sciences Journal of the first scientific paper on the anti atherosclerosis benefits of m.doc(TM) in combination with both statins and sterols. Further scientific publications concerning cholesterol lowering capabilities are set to follow in 2006.
Alltracel CEO Tony Richardson commented:
“Overall we are pleased with this quarter’s progress on revenue growth, partnership signings, dental care product development and cardiovascular research and partnership progress. We saw a solid quarter on quarter revenue increase throughout 2005 and we are looking at an exciting 2006 in which we see continued strong revenue growth driven by enterprise level deals already signed and to be signed. We remain particularly enthusiastic about the potential for the m.doc(TM) technology platform’s coronary health applications and are accelerating discussions to commercialise the technology with a number of multinational partners in 2006. We enter 2006 in a good position to achieve our first profitable year from continued revenue growth and improved cost controls in our three business sectors.”
For Further Information Contact: Dublin: Kathy Wray Alltracel: +353-1-235-2162 press@alltracel.com London: Sarah MacLeod / Davina Langdale Financial Dynamics: +44-0207-831-3113 New York: Sean Leous Financial Dynamics: +1-212-850-5626 Notes to Editors follow:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oral-Care and Coronary Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China.
Alltracel was founded in 1996 and listed on London’s Alternative Investment Market in July 2001.
m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the end product of Alltracel’s patented process and is currently targeting two major markets.
- In the Consumer HealthCare market this process applied to cotton in the form of raw cellulose is proven as an effective and efficient haemostatic (blood-stopping) agent. Here m-doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized wound care, oral care and relevant first aid brands worldwide.
- In the Coronary Health market, EU based pre-clinical and patient studies have demonstrated the m-doc(TM) technology platform success in lowering cholesterol and have indicated longer term coronary health benefits. In addition pre-clinical work showed significant indications that the m.doc(TM) coronary health benefits are additive in nature, to both statins and sterols. Further efficacy, dosage and timing/phasing studies to determine optimum delivery systems, formats and combinations in both the nutraceutical and pharmaceutical markets are underway. Development discussions with potential partners in the nutraceutical and pharmaceutical sectors in the EU, Asia and North America have commenced.
blotters(TM) is Alltracel’s branded blood stopping thin film technology for the consumer first aid and grooming markets. The blotters(TM) are small, thin, film strips (similar to breath freshener strips) impregnated with m-doc(TM) - Alltracel’s unique blood stopping ingredient and are packed in a convenient pocket-sized plastic dispenser. When placed on minor cuts e.g. shaving nicks m-doc(TM) is released on contact with the blood, forming a soft gel-like layer over the wound to stop the bleeding fast.
m-doc(TM), blotters(TM) are trademarks of Alltracel Pharmaceuticals PLC.
Alltracel Pharmaceuticals Plc.
CONTACT: For Further Information Contact: Dublin: Kathy Wray, Alltracel:+353-1-235-2162, press@alltracel.com; London: Sarah MacLeod / DavinaLangdale, Financial Dynamics: +44-0207-831-3113; New York: Sean Leous,Financial Dynamics: +1-212-850-5626
